AIFF News & Events

Firefly Neuroscience announced the advancement of research using Resting EEG/Cognitive EEG brain scans collected on its FDA-510(k)-cleared Evoke System to potentially distinguish between the three main subtypes of attention-deficit/hyperactivity disorder: hyperactive and impulsive, inattentive, and combined. Today, a diagnosis of adult ADHD is based upon meeting the following general symptoms-based criteria: symptoms should be present in two or more settings, such as home, work or school; symptoms should clearly interfere with or reduce the functioning of a person in social, work, or school-related activities; symptoms experienced cannot be better explained by another mental health condition, such as depression or anxiety; and symptoms should not only occur during the course of a psychotic disorder like schizophrenia. In addition, healthcare professionals typically use the Diagnostic and Statistical Manual of Mental Disorders to distinguish between the three types of ADHD. According to the DSM-5, adult ADHD may be diagnosed in the following cases: hyperactive and impulsive type ADHD - at least five symptoms of hyperactivity and impulsivity for more than six months without meeting the diagnostic criteria for inattentive behavior; inattentive type ADHD - at least five symptoms of inattention for more than six months without meeting the diagnostic criteria for hyperactive or impulsive behavior; and, combined type ADHD - at least five symptoms of hyperactivity and impulsivity and at least five symptoms of inattention for more than 6 months. Gil Issachar, CTO, said, "While there has been significant progress made in the treatment of ADHD over the years, there is no question that significant unmet need remains, particularly after a general diagnosis of the disorder has been made. For example, some types of ADHD respond well to stimulants, while others don't and neurofeedback therapy may be recommended instead.5 Firefly's EEG/ERP platform can leverage subtype-specific biomarker profiles to inform personalized treatment recommendations, potentially improving outcomes for the millions currently on generalized ADHD treatment plans. We believe that the technology also opens the door to ongoing treatment monitoring - allowing clinicians to objectively track whether an intervention is working at the neurological level."

Firefly Neuroscience announces a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of Evoke Neuroscience and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans. The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.

Firefly Neuroscience files $250M mixed securities shelf

Reports Q3 revenue $388,000 vs. $33,000 last year. "As demonstrated by our revenue growth, reduced cost structure and improved bottom line in Q3-2025, we have been able to rapidly integrate the Evoke business," said Greg Lipschitz, Firefly's Chief Executive Officer. "Moving forward, we remain focused on aggressively executing our commercial growth strategy, while also continuing to deploy NVIDIA's advanced software development resources and industry-leading frameworks to advance our goal of building the world's first EEG /ERP-based foundation model of the human brain."